Martínez-Consuegra N, Baquera-Heredia J, León-Bojorge B, Padilla-Rodríguez A, Ortiz HC

Language: Spanish
References: 42
Page: 269-278
PDF size: 201.60 Kb.

ABSTRACT

Objective: To correlate the expression of p53 and BCl-2 with the clinical outcome and anatomic location of the gastrointestinal stromal tumours (GIST). Background data: The GIST are the most common non-epithelial neoplasm of the gastrointestinal tract. In spite of the existence of a wide range of predictive factors, their clinical outcome is unpredictable. There are several studies that correlate the expression of p53 and Bcl-2 with the clinical outcome and anatomic location of the GIST. Methods: We obtained 19 cases from the archives of the Department of Pathology of the ABC Medical Center, in Mexico City. GIST were classified into risk groups according to the Fletcher et al. classification. We performed an immunohistochemeestry panel including CD117, CD34, actin, desmin, P-S100, p53 and BCl-2 and correlated their expression to the risk group and anatomical site of the tumors. Results: There was less expression of p53 in the gastric tumors (27%) than in small bowel tumors (100%). There was greater expression of p53 in the high-risk tumors than in the very low-risk ones, regardless of the anatomical site. Bcl-2 expression was more expressed in the small intestine tumors (100%) than in those located in the duodenum (50%) The high risk tumors showed slightly more expression of Bcl-2 than the low risk ones (89% vs. 100%), despite the anatomical location. Conclusions: Both, p53 and Bcl-2 are important markers to establish the anatomical site of GIST, and are also helpful to predict the clinical behavior of these tumors.

REFERENCES

1. Pancras CWH. The pathology of Gastrointestinal Stromal Tumors (GIST) in GIST and NET. Rare diseases as a model for translational research. 20 European Congress of Pathology 2005. Palais des Congrès de Paris, Amphithèâtre Bordeaux, Monday, 5 September 2005.

2. Shreyaskumar RP. La era de la terapia molecular: redefiniendo el tratamiento de los tumores del estroma gastrointestinal. Gaceta Mexicana de Oncología 2005; 4(Supl. 1): 11-17.

3. Rosai J. Gastrointestinal tract. In: Rosai, Ackerman (eds.). Surgical pathology. 9th Ed. Mosby; 2004, p. 674-80

4. Bucher P, Villiger P, Egger JF, Morel P Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly 2004; 134: 145-53.

5. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-19.

6. Hirota S, Isozako K, Moriyama Y, et al. Gain of function mutations of c-kit in gastrointestinal stromal tumors. Science 1998; 279: 577-80.

7. Druker Bj, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.

8. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-95.

9. Hornik JL, Fletcher CDM. The significance of KIT (CD117) in gastrointestinal stromal tumors. Int J Surg Pathol 2004; 12: 93-7.

10. Cunnigham RE, Abbondazo SL, Chu WS, et al. Apoptosis, Bcl-2 and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Imminohistochem Mol Morph 2001; 9: 19-23.

11. Feakins RM. The expression of p53 and Bcl-2 in gastrointestinal stromal tumors is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 2005; 46: 270-9.

12. Al-Bozom IA. P53 expression in gastrointestinal stromal tumors. Pathol Int 2001; 51: 519-23.

13. Lopes JM, Silva P, Seixas M, Cirnes L, Seruca R. Microsatellite instability is not associated with degree of malignancy and p53 expression of gastrointestinal stromal tumors. Histopathology 1998; 33: 579-81.

14. Emory TS, Sobin LH, Lukes L, Lee DH, O’Leary TJ Prognosis of gastrointestinal smooth –Muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7.

15. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.

16. Saul SH, Rast ML, Brooks JJ. The immunohistochemestry of gastrointestinal stromal tumors. Evidence supporting an origin from smooth muscle. Am J Surg Pathol 1987; 11: 464-73.

17. Fegnolio CM, Noffsinger AE, Stemmermann GN, et al. Gastrointestinal mesenchymal neoplasms. In: Gastrointestinal pathology. An Atlas and text. 2nd Ed. Lippincott Williams and Wilkins; 1999, p. 1169-94.

18. Robinson TL, Sicar K, Hewlett BR, et al. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol 2000; 156: 1157-63.

19. Popescu LM, Ciontea S, Cretoiu D, et al. Novel type of interstitial cell (Cajal-like) in human fallopian tube. J Cell Mol Med 2005; 9: 479-523.

20. Sircar K, Hewlett BR, Huitzinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-89.

21. Gibson PC, Cooper K. Cd117 (Kit): a diverse protein with selective application in surgical pathology. Adv Anat Pathol 2002; 9: 65-9.

22. Ramón y Cajal S. Nota sobre el plexo de Auerbach de la rana. Trabajos del Laboratorio de Histología de la Facultad de Barcelona; Febrero1892, p. 23-8.

23. Müller E. Zur Kenntnis del Ausbreitung und Endigunsweise der Magen. Darms und Pankreas-Nerven. Arch F Mikr Anat Bd XL.

24. Thuneberg L. One hundred years of intersticial cells of Cajal. Micr Res Tech 1999; 47: 223-38.

25. Joensuu H, Roberts PJ, Sarlomo-Rokala M y col. Effects of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.

26. Greenson JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 2003; 16: 366-75.

27. Hasewaga T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumors: consistent CD117 immunostainig for diagnosis and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 669-76.

28. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41-7.

29. Montgomery E, Abraham SC, Fisher C, et al. CD44 Loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 2004; 28: 168-77.

30. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathological study. Hum Pathol 1998; 29: 791-800.

31. Tanaka S, Saito K, Reed J. Structure-function analysis of the Bcl-2 oncoprotein. J Biol Chem 1993; 288: 10920-6.

32. Hockenbery D, Nunez G, Milliam C, Schreiber RD, Korsmeyer SJL. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348(6299): 334-6.

33. Cleary ML, Sklar J. Nucleotide sequence of a t (14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci, USA 1985; 82: 7439-43.

34. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci, USA 1986; 83: 5214-18.

35. Dada MA, Chetty RN, Biddolph SC, Schneider JW, Gatter KC. The immunoexpression of bcl-2 an p-53 in Kaposi’s sarcoma. Histopathology 1996; 29: 159-63.

36. Suster S, Fisher C, Moran C. Expression of Bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin. Serosal surfaces and gastrointestinal tract. Am J Surg Pathol 1998; 22: 863-72.

37. Pezella F, Tse AGD, Cordell JL, et al. Expresion of Bcl-2 oncogen protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990; 137: 225-32.

38. Dowell SP, Hall PA. The p53 tumor suppressor gene and tumor prognosis: is there a relationship? J Pathol 1995; 177: 221-4.

39. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.

40. Pezella F, Morrison H, Jones M, et al. Immunohistochemical detection of p53 and bcl-2 protein in non-Hodgkin’s lymphoma. Histopathology 1993; 22: 45-50.

41. Ray R, Tahan ST, Andrews C, Goldman H. Stromal tumor of the stomach. Prognostic value of the PCNA index. Mod Pathol 1994; 7: 26-30.

42. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemestry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.